Who Should Treat Coronary Left Main Disease – A Battle of the Titans?

P. Meier,A. Lansky,C. McGregor

DOI: https://doi.org/10.1159/000329398

2011-06-25

The Cardiology

Abstract:In a recent issue of Cardiology, Zheng et al. [3] addressed the interesting question as to whether drug-eluting stents achieve a sufficient reduction in restenosis in order to rival CABG. The authors analyzed data from 15 studies including 6,551 patients who underwent either PCI with drug-eluting stents or CABG. Noteworthy, most of these studies were observational and only 2 were prospective randomized trials. Clinical outcomes were similar between the 2 procedures. However, the risk for repeat revascularization was significantly higher for drug-eluting stent PCI than for CABG. Several aspects are important when interpreting this study. First, most data were derived from nonrandomized studies which are inheritably prone to confounding. This is considerably more critical since clinical guidelines at the time when these studies were performed advocated CABG as the preferred treatment option. Presumably many of the patients treated with PCI were turned down for surgery, and thus represent a higher-risk population. Second, the studies evaluated important endpoints such as death, myocardial infarction, stroke and need for revascularization; however, complications which can significantly impair the quality of life of the patients after bypass surgery, such as sternal wound infection, reoperation for bleeding, renal impairment, respiratory infecAndreas Grüntzig [1] pioneered in the technique of percutaneous coronary intervention (PCI) in Zurich, Switzerland, in 1977. In fact, one of Grüntzig’s first patients needed a left main (LM) intervention. The patient was a 43-year-old man with an 80% stenosis of the LM coronary artery. The diagnostic angiogram was performed on November 11, 1977. Andreas Grüntzig then proceeded with a successful PCI on November 21, 1977. He presented this case in a letter to the editor in the journal Lancet . In a subsequent report of his first 50 patients, Grüntzig described 2 patients who had a balloon angioplasty for LM disease [2] . Nonetheless, for many years, surgical coronary artery bypass grafting (CABG) remained the preferred method of treatment for LM disease. Of note, stents were not yet available in these formative years of the interventional field. With the availability of coronary stents after their first use in 1986 by Ulrich Sigwart, LM disease was treated increasingly with PCI. Notwithstanding, LM disease was always regarded as a high risk for PCI. The first studies comparing CABG with PCI demonstrated insightful outcomes, although patients treated with PCI had a significantly increased risk for restenosis. With progress in stent technology, especially the introduction of drugeluting stents, the restenosis risk has dramatically decreased in recent years. Received: May 13, 2011 Accepted: May 16, 2011 Published online: June 25, 2011